Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results from Phase 3 Trials at American Psychiatric Association Annual Meeting

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) today announced it will be presenting data on two late-stage development products, cariprazine and levomilnacipran, at the American Psy…
Read the full story: BioSpace.com Featured News